Browsing by Keyword : Receptor, ErbB-2
Showing results 1 to 14 of 14
| Pub Year | | Title | AJOU Author(s) |
| 2024 | | Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers | 안미선 |
| 2020 | | Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer | 정용식 |
| 2020 | | Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial | 강석윤 |
| 2022 | | Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer | 강석윤 |
| 2021 | | Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, her2-negative metastatic breast cancer: Subgroup analyses of kcsg-br15-10 (youngpearl) | 강석윤 |
| 2022 | | Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy | 정근옥 |
| 2019 | | Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer? | 김지영 |
| 2015 | | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | 강석윤 |
| 2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial | 강석윤 |
| 2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
| 2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
| 2016 | | Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population | 김지영 |
| 2014 | | Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. | 고영화 |
| 2016 | | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | 강석윤 |
1
